|
Synonyms: BMS-224818 | LEA29Y | Nulojix®
belatacept is an approved drug (FDA (2011), EMA (2011))
Compound class:
Peptide or derivative
Comment: A recombinant protein fusing the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). CTLA-4 is essential for T-cell co-activation.
Belatecept differs from abatacept by only 2 amino acids. 
View more information in the IUPHAR Pharmacology Education Project: belatacept |
| References |
|
1. Latek R, Fleener C, Lamian V, Kulbokas 3rd E, Davis PM, Suchard SJ, Curran M, Vincenti F, Townsend R. (2009)
Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation, 87 (6): 926-33. [PMID:19300198] |
|
2. Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, Moal MC, Mondragon-Ramirez GA, Kothari J, Polinsky MS et al.. (2016)
Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med, 374 (4): 333-43. [PMID:26816011] |
